Compare IMAX & WVE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMAX | WVE |
|---|---|---|
| Founded | 1967 | 2012 |
| Country | Canada | Singapore |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.4B |
| IPO Year | 1997 | 2015 |
| Metric | IMAX | WVE |
|---|---|---|
| Price | $35.78 | $7.30 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 16 |
| Target Price | ★ $44.50 | $29.81 |
| AVG Volume (30 Days) | 1.1M | ★ 3.6M |
| Earning Date | 04-30-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 31.25 | N/A |
| EPS | ★ 0.07 | N/A |
| Revenue | ★ $410,212,000.00 | $3,704,000.00 |
| Revenue This Year | $9.79 | N/A |
| Revenue Next Year | $7.51 | $85.67 |
| P/E Ratio | $511.86 | ★ N/A |
| Revenue Growth | 16.47 | ★ 149.43 |
| 52 Week Low | $24.20 | $5.02 |
| 52 Week High | $43.16 | $21.73 |
| Indicator | IMAX | WVE |
|---|---|---|
| Relative Strength Index (RSI) | 42.24 | 41.79 |
| Support Level | $33.64 | $6.81 |
| Resistance Level | $37.52 | $7.67 |
| Average True Range (ATR) | 1.50 | 0.36 |
| MACD | -0.07 | 0.19 |
| Stochastic Oscillator | 36.77 | 54.32 |
Imax Corp is a technology platform for entertainment and events. Through its proprietary software, auditorium architecture, patented intellectual property, and specialized equipment, IMAX offers end-to-end solution to create superior, immersive content experiences for which the IMAX brand is globally renowned. The Company has two reportable segments being Content Solutions and Technology Products and Services. The Company leverages its proprietary technology and engineering in all aspects of its business, which principally consists of the IMAX film remastering and the sale or lease of premium IMAX theater systems.
WAVE Life Sciences Ltd is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.